Reflective of the current economic boom cited by Trump II, JSR LifeSciences is taking a 50% haircut on a company it bought in 2017 for $400 million. It will sell Crown Bioscience to a Chinese clinical research organization owned by The Carlyle Group, a politically connected private equity underwriter (PEU). The total price is $204 million spread over a two year period.
JSR Life Sciences LLC ("JSR Life Sciences"), a global leader in life sciences materials and services, today announced it has entered into a definitive agreement to transfer Crown Bioscience Inc. ("Crown Bioscience") to Adicon Holdings Limited ("Adicon"), a premier independent clinical laboratory provider in China and a portfolio company of The Carlyle Group. The transaction, subject to customary closing conditions, is expected to close in 2026.
I think they call that an implosion which can also make a kaboom sound. Crown Biosciences global headquarters is in San Diego, California.
Acquirer Adicon's website says this about the company:
Adicon has three major service platforms: a research and development center, clinical drug testing, and testing services. The testing services platform includes clinical laboratories, pathology laboratories, reproductive genetics laboratories, gene laboratories, and mass spectrometry laboratories, holding over 200 patents and providing over 4,000 testing items.
Carlyle invested in Adicon in 2018, Have they written down half the value of their clinical company like JSR did with Crown?
The greater question is whether Trump II will allow a U.S. headquartered clinical research company to be taken over by a Chinese firm, even one owned by a D.C. based PEU.
Glenn Youngkin was co-CEO of Carlyle in 2018 when they invested in Adicon. Carlyle's press release stated in October 2018:
As one of the first and most active international private equity investors in China, Carlyle has adopted a local approach towards investments in China for two decades. Carlyle has invested more than US$8 billion of equity in nearly 100 private equity transactions across China through its US dollar and RMB investment vehicles as of June 30, 2018.Youngkin ran away from his record of exporting U.S. jobs to China as a candidate for Virginia Governor in 2021. His general un-likability has not worsened from his China moves while a Carlyle top dog (they've remained hidden).
Carlyle had the magic touch in the past in regard to getting controversial deals approved. Flashback to 2007 when the U.S. had an uproar over Dubai Ports World buying six port operations. Months later Carlyle sold Landmark Aviation and Standard Aero with fifty U.S. airport operations to Dubai Aerospace. That's what happens when you are close with the President.